12 Month Price Forecast For VTRS
Distance to VTRS Price Forecasts
VTRS Price Momentum
🤔 Considering Viatris (VTRS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 9:37 PM UTC
VTRS Analyst Ratings & Price Targets
Based on our analysis of 12 Wall Street analysts, VTRS has a consensus that is neutral. The median price target is $14.00, with forecasts ranging from $12.00 to $15.00. Currently, there are 2 Buy ratings, 6 Hold ratings, and 2 Sell ratings.
With VTRS currently trading at $12.82, the median price forecast suggests a 9.2% upside. The most optimistic forecast comes from Glen Santangelo at Jefferies, projecting a 17.0% upside, while Balaji Prasad at Barclays provides the most conservative target, suggesting a -6.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VTRS Analyst Consensus
VTRS Price Target Range
Latest VTRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VTRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 6, 2024 | Piper Sandler | David Amsellem | Neutral | Reiterates | $14.00 |
| Nov 8, 2024 | Barclays | Balaji Prasad | Underweight | Maintains | $12.00 |
| Jul 19, 2024 | Jefferies | Glen Santangelo | Buy | Reinstates | $15.00 |
| Mar 28, 2024 | Piper Sandler | David Amsellem | Neutral | Reiterates | $13.00 |
| Nov 22, 2023 | Piper Sandler | David Amsellem | Neutral | Maintains | $11.00 |
| Oct 23, 2023 | B of A Securities | Jason Gerberry | Underperform | Downgrade | $9.00 |
| Jun 23, 2023 | Barclays | Balaji Prasad | Underweight | Downgrade | $11.00 |
| Apr 25, 2023 | Barclays | Balaji Prasad | Equal-Weight | Downgrade | $11.00 |
| Apr 24, 2023 | Barclays | Balaji Prasad | Equal-Weight | Downgrade | $11.00 |
| Feb 28, 2023 | Barclays | Balaji Prasad | Overweight | Maintains | $16.00 |
| Feb 17, 2023 | BMO Capital | Gary Nachman | Market Perform | Downgrade | $14.00 |
| Feb 1, 2023 | Barclays | Balaji Prasad | Overweight | Maintains | $15.00 |
| Jan 27, 2023 | Jefferies | Glen Santangelo | Buy | Upgrade | $15.00 |
| Nov 15, 2022 | JP Morgan | Chris Schott | Neutral | Maintains | $14.00 |
| Nov 10, 2022 | UBS | Ashwani Verma | Neutral | Upgrade | $12.00 |
| Nov 8, 2022 | Piper Sandler | David Amsellem | Neutral | Upgrade | $10.00 |
| Oct 25, 2022 | Barclays | Balaji Prasad | Overweight | Maintains | $16.00 |
| Oct 21, 2022 | Jefferies | Glen Santangelo | Hold | Initiates | $11.00 |
| Aug 9, 2022 | BMO Capital | Gary Nachman | Outperform | Maintains | $16.00 |
| Jun 14, 2022 | UBS | Sell | Initiates | $0.00 |
Viatris Inc (VTRS) Financial Data
Viatris Inc has a market capitalization of $15.22B with a P/E ratio of 235.8x. The company generates $15.05B in trailing twelve-month revenue with a -5.9% profit margin.
Revenue growth is -4.8% quarter-over-quarter, while maintaining an operating margin of +13.9% and return on equity of -4.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Viatris Inc (VTRS) Company Overview
About Viatris Inc
Provides a wide range of pharmaceutical products.
The company operates through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets, generating revenue by offering a diverse portfolio of prescription brand drugs, generic medications, complex generics, biosimilars, and APIs. Viatris distributes its products to various channels including pharmacies, wholesalers, and institutions, capitalizing on both established and emerging markets.
Viatris boasts a comprehensive therapeutic range addressing noncommunicable and infectious diseases, with well-known products such as Lyrica, Lipitor, and EpiPen. The company also engages in collaboration and licensing agreements with other pharmaceutical firms, enhancing its product offerings and market reach. Founded in 1961, it is headquartered in Canonsburg, Pennsylvania.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
32,000
CEO
Mr. Scott Andrew Smith Ph.D.
Country
United States
IPO Year
1980
Website
www.viatris.comViatris Inc (VTRS) Latest News & Analysis
Mapi Pharma is Seeking New Depot Product Partnerships
11 days agoManagement will participate in the 7th Annual Evercore HealthCONx Conference, indicating engagement with investors and industry peers in the healthcare sector.
Participation in a prominent conference can signal company growth potential, attract investor interest, and provide insights into strategic direction, impacting stock performance.
2 Generic Drug Stocks Ready to Surge in 2025
16 days agoGeneric and biosimilar drugs are favored for their lower costs. Generics replicate brand names exactly, while biosimilars are similar but may need clinical trials.
Increased demand for generics and biosimilars can pressure brand-name drug prices, impacting pharmaceutical revenue and profit margins, thus influencing investor sentiment and stock valuations.
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe
21 days agoBritain's competition watchdog fined Viatris £1.5 million ($1.88 million) for violating an order during the investigation of Theramex's acquisition of Viatris's women's healthcare products.
The fine signals regulatory scrutiny in M&A activities, potentially affecting future deals and investor confidence in the pharmaceutical sector's compliance landscape.
Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)
22 days agoViatris Inc. executives participated in the Jefferies London Healthcare Conference on November 21, 2024, discussing company performance and strategy.
The Jefferies London Healthcare Conference offers insights into Viatris Inc.'s strategic direction and potential growth, influencing investor sentiment and stock performance.
Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)
28 days agoViatris Inc. (NASDAQ: VTRS) will participate in the UBS Global Healthcare Conference on November 12, 2024, at 11:45 AM ET, with CFO Doretta Mistras presenting.
Viatris' participation in the UBS Global Healthcare Conference signals engagement with investors, potentially influencing stock sentiment and providing insights into its strategic direction.
Bargain Priced Viatris Reports Strong Q3 Earnings Results
1 month agoViatris reported strong Q3 earnings results, indicating robust financial performance. The stock is currently considered a bargain.
Strong Q3 earnings indicate solid financial health for Viatris, potentially attracting investors seeking undervalued stocks and signaling growth potential in the pharmaceutical sector.
Frequently Asked Questions About VTRS Stock
What is Viatris Inc's (VTRS) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Viatris Inc (VTRS) has a median price target of $14.00. The highest price target is $15.00 and the lowest is $12.00.
Is VTRS stock a good investment in 2025?
According to current analyst ratings, VTRS has 2 Buy ratings, 6 Hold ratings, and 2 Sell ratings. The stock is currently trading at $12.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for VTRS stock?
Wall Street analysts predict VTRS stock could reach $14.00 in the next 12 months. This represents a 9.2% increase from the current price of $12.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viatris Inc's business model?
The company operates through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets, generating revenue by offering a diverse portfolio of prescription brand drugs, generic medications, complex generics, biosimilars, and APIs. Viatris distributes its products to various channels including pharmacies, wholesalers, and institutions, capitalizing on both established and emerging markets.
What is the highest forecasted price for VTRS Viatris Inc?
The highest price target for VTRS is $15.00 from Glen Santangelo at Jefferies, which represents a 17.0% increase from the current price of $12.82.
What is the lowest forecasted price for VTRS Viatris Inc?
The lowest price target for VTRS is $12.00 from Balaji Prasad at Barclays, which represents a -6.4% decrease from the current price of $12.82.
What is the overall VTRS consensus from analysts for Viatris Inc?
The overall analyst consensus for VTRS is neutral. Out of 12 Wall Street analysts, 2 rate it as Buy, 6 as Hold, and 2 as Sell, with a median price target of $14.00.
How accurate are VTRS stock price projections?
Stock price projections, including those for Viatris Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
